The dose regimen formulation of doxycycline hydrochloride and florfenicol injection based on ex vivo pharmacokinetic-pharmacodynamic modeling against the Actinobacillus pleuropneumoniae in pigs
Authors:
Open Access
- 24 February 2023
- journal article
- research article
- Published by Springer Nature in Animal Diseases
- Vol. 3 (1) , 1-13
Abstract
Doxycycline hydrochloride and florfenicol combination (DoxHcl&FF) is an effective treatment for respiratory diseases. In the study, our objective was to evaluate the activity of DoxHcl&FF against Actinobacillus pleuropneumoniae (APP) in porcine pulmonary epithelial lining fluid (PELF) and the optimal dosage scheme to avoid the development of resistance. The DoxHcl&FF was administered intramuscularly (IM) at 20 mg/kg, and the PELF was collected at different time points. The minimum inhibitory concentration (MIC) and time-mortality curves were also included in the study. Based on the sigmoid Emax equation and dose equations, the study integrated the in vivo pharmacokinetic data of infected pigs and ex vivo pharmacodynamic data to obtain the area under concentration time curve (AUC0-24h)/MIC values in PELF and achieve bacteriostatic activity, bactericidal activity and the virtual eradication of bacteria. The study showed that the combination of DoxHcl and FF caused no significant changes in PK parameters. The peak concentration (Cmax) of FF in healthy and diseased pigs was 8.87 ± 0.08 μg/mL and 8.67 ± 0.07 μg/mL, the AUC0-24h were 172.75 ± 2.52 h·μg/mL and 180.22 ± 3.13 h·μg/mL, the Cmax of DoxHcl was 7.91 ± 0.09 μg/mL and 7.99 ± 0.05 μg/mL, and the AUC0-24h was 129.96 ± 3.70 h·μg/mL and 169.82 ± 4.38 h·μg/mL. DoxHcl&FF showed strong concentration-dependent tendencies. The bacteriostatic, bactericidal, and elimination activity were calculated as 5.61, 18.83 and 32.68 h, and the doses were 1.37 (bacteriostatic), 4.59 (bactericidal) and 7.99 (elimination) mg/kg. These findings indicated that the calculated recommended dose could assist in achieving more precise administration, increasing the effectiveness of DoxHcl&FF treatment for APP infections.Keywords
Funding Information
- National Natural Science Foundation of China (32072920)
- Key Technologies Research and Development Program (2017YFD0501402)
- Fundamental Research Funds for the Central Universities (2662022DKPY007)
- Huazhong Agricultural University (SZYJY2022024)
This publication has 28 references indexed in Scilit:
- Pharmacodynamics of Doxycycline and Tetracycline against Staphylococcus pseudintermedius: Proposal of Canine-Specific Breakpoints for DoxycyclineJournal of Clinical Microbiology, 2013
- Impact of Meropenem in Combination with Tobramycin in a Murine Model of Pseudomonas aeruginosa PneumoniaAntimicrobial Agents and Chemotherapy, 2013
- Profiling microRNAs in lung tissue from pigs infected with Actinobacillus pleuropneumoniaeBMC Genomics, 2012
- In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureusThe Journal of Antibiotics, 2010
- Efficacy of metaphylactic florfenicol therapy during natural outbreaks of bovine respiratory diseaseJournal of Veterinary Pharmacology and Therapeutics, 2008
- Tissue concentrations: do we ever learn?Journal of Antimicrobial Chemotherapy, 2007
- Evaluation of the antimicrobial activity of florfenicol against bacteria isolated from bovine and porcine respiratory diseaseVeterinary Microbiology, 2005
- Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicineJournal of Veterinary Pharmacology and Therapeutics, 2004
- Pharmacokinetics of Florfenicol in Healthy Pigs and in Pigs Experimentally Infected with Actinobacillus pleuropneumoniaeAntimicrobial Agents and Chemotherapy, 2003
- The pharmacokinetic–pharmacodynamic approach to a rational dosage regimen for antibioticsResearch in Veterinary Science, 2002